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Background
Immunotherapies have improved patient responses and sur-
vival, though not all patients benefit. Effective biomarkers may
help to improve outcomes. Durvalumab is a human IgG1 mono-
clonal antibody that inhibits PD-L1 binding to PD-1 and CD80,
restoring antitumor immunity [1, 2]. PD-L1 expression on tumor
or tumor-infiltrating immune cells measured manually with dif-
ferent immunohistochemistry (IHC) assays can enrich for pa-
tients responding to anti-PD-1/PD-L1 agents. Tumor-infiltrating
cytotoxic CD8+ T cells may also have potential predictive utility
for therapeutic response. We explored automated image ana-
lysis and pattern recognition of tumor biopsies to determine
whether CD8+ and PD-L1+ cell densities could better identify
patients most likely to respond to durvalumab than PD-L1 IHC
alone.
Methods
CP1108/NCT01693562 was a nonrandomized phase I/II trial
evaluating durvalumab in advanced NSCLC and other solid© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zetumors [3]. By 29APR2016, 304 previously treated NSCLC pa-
tients, median 3 prior lines, received 10 mg/kg of durvalumab
q2w ≤12 months. Baseline archived or fresh tumor biopsies
were analyzed for PD-L1 (Ventana/SP263) and CD8 (Ventana/
SP239) by IHC. For the marker combination, slides were scored
using the product of PD-L1+ and CD8+ cell densities with
Definiens’ Developer XD 2.1.4 software. For PD-L1 alone, ≥25%
tumor cells stained for PD-L1 at any intensity were scored posi-
tive. Clinical outcomes (ORR, PFS and OS) were analysed based
on CD8+ and PD-L1+ densities (n = 163 available) and PD-L1
alone in pre-treatment biopsies using a discovery (n = 84) and
validation (n = 79) set. Datasets were matched on baseline PD-
L1 status, histology, ECOG, lines of therapy, and response.
Results
Patients with high pretreatment CD8+ and PD-L1+ densities (preva-
lence = 36%) had better ORR, OS, and PFS compared to those with
low CD8+ and PD-L1+ densities (Fig. 1), as well as high PD-L1 expres-
sion alone.
Conclusions
Automated image analysis of CD8+ and PD-L1+ cell densities in
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OS, no. of events 155 179
Median (95 % CI), months 10.3 (8.0-11.8) 7.4 (6.1-8.3)
HR (95 % CI) 0.73 (0.59-0.91); P = 0.0022
PFS, no. of events 218 219
Median (95 % CI), months 2.1 (2.0-2.2) 3.3 (2.3-3.5)
HR (95 % CI) 0.98 (0.81-1.19); P = 0.42
ORR (95 % CI) 21.1 % (16.4-26.5) 11.4 % (7.9-15.8)
Treatment difference, % (95 % CI) 9.6 (3.5-15.9); P = 0.0011
Fig. 1 (abstract O1). Clinical outcomes in CD8+/PD-L1+ or PD-L1
NSCLC patient subsets
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Background
There is no standard second-line therapy for advanced urothe-
lial cancer. Although paclitaxel, docetaxel, and vinflunine are
commonly used, they provide limited clinical benefit. KEYNOTE-
045 compared the efficacy and safety of the anti–PD-1 antibody
pembrolizumab versus investigator-choice chemotherapy as
second-line therapy for advanced urothelial cancer that pro-
gressed or recurred following first-line platinum-based
chemotherapy.Methods
Eligible patients were enrolled regardless of PD-L1 expression and
randomized 1:1 to pembrolizumab 200 mg Q3W for 24 months
or investigator’s choice of paclitaxel 175 mg/m2 Q3W, docetaxel
75 mg/m2 Q3W, or vinflunine 320 mg/m2 Q3W. Randomization
was stratified by ECOG PS (0/1 vs 2), liver metastases (yes vs no),
hemoglobin level (<10 vs ≥10 g/dL), and time from last chemo-
therapy dose (<3 vs ≥3 months). The study had a group sequen-
tial design to control for type I error. Primary endpoints were OS
and PFS (RECIST v1.1 by blinded, independent central review).
ORR was a key secondary endpoint. Differences in OS and PFS
were assessed in the intention-to-treat population using the
stratified log-rank test
Results
Between November 5, 2014 and November 13, 2015, 542
patients from 29 countries were enrolled: 270 in the pembrolizu-
mab arm, 272 in the chemotherapy arm. As of September 7,
2016, median follow-up was 9.0 months; 49 (18.4%) patients
remained on pembrolizumab and 3 (1.2%) patients remained on
chemotherapy. Baseline characteristics were generally balanced
between arms, with 87.3% with visceral disease, 34.3% with liver
metastases, 1.1% with ECOG PS 2, 81.5% with hemoglobin
≥10 g/dL, and 38.2% with <3 months since most recent chemo-
therapy. Pembrolizumab significantly improved OS over chemo-
therapy (HR 0.73, P = 0.0022; median 10.3 vs 7.4 months) (Table
1). There was no difference in PFS (HR 0.98, P = 0.42) (Table 1).
ORR was significantly improved with pembrolizumab (21.1% vs
11.4%) (Table 1). Pembrolizumab was associated with fewer any-
grade (60.9% vs 90.2%) grade 3-5 treatment-related AEs (15.0%
vs 49.4%). 4 patients in each arm died due to treatment-related
AEs.
Conclusions
Pembrolizumab demonstrated a statistically significant OS bene-
fit over chemotherapy in the second-line advanced urothelial
cancer setting, making it the first therapy to demonstrate a
survival benefit over an active comparator in this population.
The superior OS combined with the lower rate of any-grade
and high-grade treatment-related AEs support pembrolizumab
as a new standard of care for advanced urothelial cancer that
progressed on/after platinum-based chemotherapy.
Trial registration
ClinicalTrials.gov identifier: NCT02256436
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Background
Nivolumab is a programmed death-1 (PD-1) immune checkpoint in-
hibitor associated with clinical benefit in previously treated patients
with metastatic urothelial carcinoma [1]. Preclinical and clinical data
indicate that the combination of nivolumab plus ipilimumab, an anti-
cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody, can improve an-
titumor activity in other tumor types. Here, we report the first effi-
cacy and safety results of combined nivolumab plus ipilimumab
given at two different dosing schedules in CheckMate 032 , an open-
label, multicenter, phase I/II study of patients with metastatic urothe-
lial carcinoma who progressed after prior platinum-based therapy.
Methods
Patients with locally advanced or metastatic urothelial carcinoma pre-
viously treated with platinum-based therapy were included in the
study. Patients were treated with either of two combination sched-
ules, nivolumab 1 mg/kg + ipilimumab 3 mg/kg (N1I3) or nivolumab
3 mg/kg + ipilimumab 1 mg/kg (N3I1) every 3 weeks for four cycles,
followed by nivolumab 3 mg/kg every 2 weeks; or they were treated
with nivolumab monotherapy 3 mg/kg (N3) every 2 weeks. All pa-
tients were treated until disease progression or unacceptable toxicity.
The primary endpoint was investigator-assessed objective response
rate (ORR) by RECIST v1.1. Secondary endpoints included safety and
duration of response (DoR).
Results
Minimum follow-up was 3.9 months in the N1I3 (n = 26) group,
14.5 months in the N3I1 group (n = 104), and 13.8 months in N3
group (n = 78). ORR was 38.5% (95% confidence interval [CI], 20.2-
59.4), 26.0% (95% CI, 17.9-35.5), and 25.6% (95% CI, 16.4-36.8) in the
N1I3, N3I1, and N3 groups, respectively. Median DoR has not been
reached in any treatment group. The frequency of drug-related grade
3-4 adverse events was 30.8% (N1I3), 31.7% (N3I1), and 23.1% (N3).
Treatment-related adverse events led to discontinuation in 7.7%
(N1I3), 13.5% (N3I1), and 3.8% (N3) of patients. One death was re-
ported in the N3I1 group (pneumonitis) and two deaths were re-
ported in the N3 group (pneumonitis and thrombocytopenia).Conclusions
Second-line treatment with N1I3 may provide the most favorable
benefit-risk ratio among the regimens studied. If these interim results
are confirmed with longer follow-up, further development of the
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Background
While antibody blockade of the CTLA-4 and PD-1 pathways has
emerged as an effective treatment modality for cancer, the majority
of patients do not derive long-term benefit, suggesting a need for
targeting of additional immune checkpoints. Employing our unique
computational algorithms to define new members of the B7/CD28
family, we identified PVRIG, which is expressed by multiple subsets
of T and NK cells. We report here its expression pattern, functional
characterization, and anti-tumor activity of blocking antibodies tar-
geting this molecule.
Methods
Utilizing Compugen’s Predictive Discovery platform we identified
PVRIG as a potential novel immune checkpoint, after which a retro-
viral cell screening library was used to identify its cognate binding
counterpart. Target effects on T cell modulation were assessed with
primary and tumor-derived T cell assays, taking advantage of target
overexpression, knockdown, and antagonist antibody approaches.
Antibodies against the human protein were screened for their ability
to enhance T cell activation in vitro, while antibodies targeting the
mouse orthologue were assessed in vivo for effects on tumor growth
inhibition in syngeneic models.
Results
A PVRIG-Fc-fusion protein was found to bind PVRL2, with binding
specificity confirmed both by ELISA and flow cytometry analysis.
PVRIG demonstrated unique expression kinetics upon T cell activa-
tion, with detection of the target on memory T cells, as well as on
NK cells and γδ T cells. A panel of high affinity human antibodies
with the ability to block interaction of PVRIG with PVRL2 were gener-
ated, which when tested in vitro were shown to enhance activation
of both primary CD4+ and tumor-derived CD8+ T cells through a
PVRL2-dependent mechanism. The lead antibody, COM-701, is
Fig. 2 (abstract O5). Maximum percent reduction in target lesions
from baselinea
Fig. 3 (abstract O5). Percent change from baseline in target lesions
over time
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cross-reactive, in vivo studies were conducted with a surrogate block-
ing anti-mouse PVRIG antibody. When combined with anti-PD-L1
blockade, anti-mouse PVRIG inhibits growth of established tumors in
both the CT26 and MC38 colorectal cancer models. Combination
testing with additional immune checkpoint inhibitors, as well as in
PVRIG knockout mice, is ongoing.
Conclusions
We describe the identification of PVRIG as a novel immune check-
point on T cells, as well the development of a high affinity antagonis-
tic antibody, COM-701, that is currently in preclinical development.
COM-701 is able to enhance human T cell activation, and a surrogate
antibody with similar characteristics shows synergy with PD-L1
in vivo in multiple syngeneic models. Overall, our data demonstrate
the utility of targeting PVRIG in addition to other B7 family check-
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Background
Natural killer (NK) cells and the innate immune system play a critical
role in immunosurveillance, control of tumor growth, and metastasis.
NK-cell activation is negatively regulated by inhibitory killer-cell
immunoglobulin-like receptors (KIRs); therefore, blocking KIR function
may potentiate an anti-tumor immune response and complement
other immuno-oncology therapies that enhance T cell activity. We
present preliminary efficacy results in patients with squamous cell
carcinoma of the head and neck (SCCHN) from a phase I/II study of
lirilumab, a fully human monoclonal antibody that blocks inhibitory
KIRs on NK cells, in combination with nivolumab, a fully human IgG4
monoclonal antibody that targets the PD-1 receptor, in patients with
solid tumors (NCT01714739).
Methods
During dose escalation, patients with advanced solid tumors who
progressed after ≥ 1 prior therapy received lirilumab 0.1–3.0 mg/kg
once every 4 weeks (Q4W) plus nivolumab 3.0 mg/kg Q2W. Cohort
expansion was initiated at the maximum dose of lirilumab 3.0 mg/kg
Q4W plus nivolumab 3.0 mg/kg Q2W in patients with advanced solid
tumors. Key study endpoints include safety (primary), objective re-
sponse rate (ORR), disease control rate (DCR), duration of response
(DOR), and biomarker assessments.Results
As of the August 30, 2016 data cutoff, 159 patients were treated with
the lirilumab plus nivolumab combination. Treatment-related adverse
events (TRAEs) and grade 3–4 TRAEs were reported in 72% (114/159)
and 15% (24/159) of patients, respectively. Discontinuations due to
TRAEs occurred in 8% (12/159). Of the 41 patients with SCCHN
treated, 29 were evaluable for response. In this heavily pretreated,
checkpoint inhibitor–naïve group, ORR was 24% (7/29; confirmed
and unconfirmed) and DCR was 52% (15/29). Maximum reduction in
target lesions are presented in Fig. 2 for 26 patients with available
tumor assessments. Two patients classified as stable disease per
RECIST v1.1 showed unconventional responses, with 100% and 37%
reductions in target lesions. Among evaluable patients, five (17%)
had reductions in tumor burden > 80%. Responses appear durable,
with the median DOR not reached (Fig. 3). Updated efficacy and pre-
liminary biomarker analyses (including PD-L1 and HPV status) will be
presented.
Conclusions
Preliminary efficacy of lirilumab plus nivolumab in patients with ad-
vanced platinum-refractory SCCHN demonstrates clinical benefit, with
encouraging response rates that were deep and durable responses
in some patients. This combination demonstrated a manageable
safety profile similar to that observed with nivolumab monotherapy.
Further evaluation of this novel combination of an NK-cell inhibitor
and an immune checkpoint inhibitor is ongoing.
Trial Registration
ClinicalTrials.gov identifier: NCT01714739
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Background
Low tumor infiltrating lymphocytes (TIL) are predictive for poor
response to immunotherapy with anti-PD-1/PD-L1 agents. We
have shown that melanoma patients with a low frequency of PD-
1hiCTLA-4 + TIL are unlikely to respond to pembrolizumab
(Daud2016). Intratumoral electroporation of pIL-12 (IT-pIL12-EP)
leads to an IFN-g signature suggestive of increased TIL as well as
regression in both treated and untreated lesions. We hypothesize
that combination IT-pIL12-EP and pembrolizumab will improve
clinical outcomes in this low-response population. Preliminary re-
sults from a multi-center, phase II, open-label trial testing this hy-
pothesis are presented.
Methods
Melanoma stage III/IV patients with accessible lesions were con-
sented and enrolled if they had a TIL status of hiCTLA-4+ in the
CD45 + CD8 + CD3+ gate by flow cytometry (FC). Patients were
treated with pembrolizumab (200 mg every 3 weeks) concurrently
with IT-pIL12-EP on days 1, 5 and 8 every 6 weeks. Patients were
evaluated for overall response rate (ORR) every 12 weeks by
RECISTv1.1. Pre and post-treatment blood and tumor specimens were
collected, and analyzed for immune phenotyping, gene expression,
TCR diversity, and changes in the tumor microenvironment with
multispectral immunohistochemistry.
Results
Interim ORR data is available on 15 patients. 13/15 patients had
a frequency of PD-1hi CTLA-4+ TIL of < 22% (low TIL status),
phenotypes associated with a low probability of response to
anti-PD-1 (Daud 2016). These 15 patients age 39-89 years, were
53% male, 66% stage III and 34% stage IV. Treatment was well
tolerated; 38% of adverse events (AE) were classified as treat-
ment site reactions (grade 1-2) that resolved. One SAE of cellu-
litis resolved with 5d antibiotics. One grade 3 AE of diarrhea
resolved with corticosteroids. The ORR was 40% (4CR, 2PR) by
RECISTv1.1. Analysis of tumor biopsies and blood demonstrated
meaningful immunological changes including an increased num-
ber and ratio of CD8+:PD-L1+ and CD8+:FoxP3 + TIL, tumoral
RNA signatures indicating an increase in CD8 and IFN-γ-related
gene expression and concordant immune phenotypes in the
periphery.
Conclusions
The combination IT-pIL12-EP with pembrolizumab in patients with
an anti-PD-1 non-responsive phenotype engendered a 40% clinical
response with associated positive immune-based biomarker data
and an excellent safety profile. These data suggests that IT-pIL12-EP
modulates the tumor microenvironment to enable an effective anti-
PD-1 mAb response in patients otherwise unlikely to respond.
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Background
CD4+ T cells are critical components of anti-tumor immunity and play
a pivotal role in orchestrating anti-tumor immune responses. Mount-
ing evidence from preclinical and clinical studies indicates that CD4+
T cells in combination with chemotherapy can control tumor growth
and recurrence. CD4+ T cells are suggested to mediate tumor rejec-
tion through mechanisms that include cytotoxic effects on tumor
cells, inhibition of angiogenesis, and reprogramming of the tumor
microenvironment.
Methods
In this project, we set out to study the cellular and molecular mecha-
nisms underlying the therapeutic effect of chemo-immunotherapy in
the form of cyclophosphamide (CTX) and tumor specific CD4+ T cells
in a murine model of colorectal cancer. Mice were injected subcuta-
neously with colorectal cancer cells. When the tumor reached 140-
160 mm2 in area, mice were injected with a low dose of cyclophos-
phamide followed by adoptive transfer of tumor reactive CD4+ T
cells.
Results
In a murine model of colorectal cancer, we show that the combin-
ation therapy of CTX and tumor reactive CD4+ T cells resulted in en-
hanced necrosis of tumor cells in vivo, leading to eventual
eradication of advanced tumors. By using immunofluorescence stain-
ing and blood perfusion imaging, we demonstrated that the combin-
ation therapy leads to destruction of the established tumor
vasculature and reduced blood supply to tumor tissue. Furthermore,
we assessed blood vessel permeability in the tumor tissue and found
that the combination therapy increased extravasation of Evans blue
dye, suggesting an increase in vascular permeability.
Conclusions
In summary, our findings suggest that the combination therapy of
CTX + CD4+ T cells leads to destruction of the tumor vasculature,
resulting in extensive necrosis of tumor tissue and eventual tumor re-
gression. These findings may provide new insights into mechanisms
of tumor rejection by CD4+ T cells.
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Background
Immunotherapy has become an effective cancer therapy, particularly
in the case of checkpoint blockade and adoptive T cell therapy (ACT).
ACT exploits the presence of tumor-infiltrating lymphocytes (TIL) by
exponentially expanding their numbers ex vivo and re-infusing them
into the patient in an autologous setting. With the effectiveness of
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 2):91 Page 228 of 242TIL therapy already well established in multiple phase II studies in
melanoma, there is a push to translate it to other cancers in dire
need of improved therapies. Pancreatic ductal adenocarcinoma
(PDAC) is one such cancer for which the current therapy, surgery and
chemotherapy, provides an overall 5-year survival rate of only 5%.
The presence of TIL is correlated with increased survival in PDAC,
which suggests that TIL could effectively control the disease and pro-
vides a rationale to test TIL therapy in this setting.
Methods
To assess the feasibility, we characterized the immune component of
PDAC, explored the ability to grow and expand TIL from tumor frag-
ments, and analyzed the clonality of these expanded TIL.
Results
Flow cytometry analysis detected low, CD4-rich T cell infiltration. These
TIL were able to be expanded ex vivo and the addition of an agonistic
anti-41BB antibody to the cultures preferentially increased total TIL out-
growth, particularly that of CD8+ TIL. The success rate of TIL growth
was increased from 23% to 50% for cultures grown without and with
anti-41BB respectively. Sequencing of the T cell receptor CDR3-beta
chain found specific T cell clones enriched at the tumor site in compari-
son to the blood. IHC staining for MHC class I (MHCI) on PDAC tumor
samples showed that it is widely expressed but at low levels generally.
Conclusions
In conclusion, it is possible to expand CD8+ T cells from PDAC bear-
ing TCR sequences highly enriched in the tumor. Additionally, ex-
panded TIL would be able to target tumor cells as they are shown to
express MHCI. Although there are barriers yet to overcome, the initial
data suggest the feasibility of TIL therapy for PDAC.
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Background
Chimeric antigen receptor T cells (CAR-T) have shown impressive effi-
cacy against numerous hematological malignancies, yet a high per-
centage of individuals receiving these therapies experience toxicity
in the form of cytokine release syndrome (CRS) and/or normal tissue
destruction. Furthermore, solid tumors represent a substantive chal-
lenge for CAR therapy due to a lack of tumor- specific antigens and
general inability of T cells to overcome immunosuppressive tumor
microenvironments. We have sought to circumvent these obstacles
by utilizing synthetic biology approaches to augment CAR-T function
and specificity.
Methods
We developed two platform technologies that aim to mitigate tox-
icity associated with CAR-T therapy and endow T cells with environ-
mental sensing capabilities that enhance tumor discrimination from
normal tissue and/or confer the ability to generate customizable re-
sponse outputs. Firstly, we engineered an “ON-switch” CAR that con-
sists of two protein modules that undergo heterodimerization and
become competent for signaling only in the presence of a small-
molecule dimerizing agent [1]. In addition, we created a “synthetic
Notch” (synNotch) receptor, which we previously described in the
context of combinatorial antigen sensing [2], that is capable of driv-
ing expression of any number of downstream polypeptides in re-
sponse to antigen engagement.Results
Here we describe advances in our ON-switch CAR design that allow
for dose-dependent antigen-specific T cell activation in the presence
of an FDA-approved non-immunosuppressive small molecule dimeri-
zer. Furthermore, we demonstrate that our synNotch T cells are able
to deliver therapeutic payloads capable of, but not limited to, modu-
lating the tumor microenvironment and changing the cell-intrinsic
transcriptional properties of the synNotch T cells.
Conclusions
We have successfully identified a heterodimerizing switch receptor
that specifically activates T cells in the presence of an FDA-approved
non-immunosuppressive small molecule. The ability to control the
potency of the CAR-mediated immune response in this way may re-
duce the toxicity associated with CAR-T therapy. Furthermore, we
have demonstrated that synNotch T cells are able to sculpt the anti-
tumor immune response in both a T cell intrinsic (transcriptional pro-
graming) and T cell extrinsic (therapeutic payload) manner, providing
a customizable platform for altering T cell function and the tumor
microenvironment.
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Background
Thyroid cancer is the most common endocrine-related cancer with
64,330 diagnoses expected this year. While the majority of these can-
cers are curable, almost 2% of these cancers are anaplastic thyroid
cancers, which are highly aggressive and almost uniformly lethal. At
the same time, the thyroid is known for being inherently immuno-
genic. For these reasons and due to an active surgical practice pro-
viding regular resections of thyroid cancers, we undertook a study of
thyroid cancer with the idea of developing an immunotherapy for
this disease.
Methods
We have developed a thyroid cancer tumor bank to complement our
Oral, Head and Neck Cancer Program. This tumor bank cryopreserves
enzymatically isolated viable cells from resected tumors (n = 16).We
are also attempting to develop primary cell lines and are isolating
and assessing autologous tumor-specific functions of tumor-
infiltrating lymphocytes (TIL) (n = 7).
Results
To date we have established 3 tumor cell lines from thyroid cancer
specimens and identified PD-L1 expression on 2 of 2 tested. While
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be generated from 85% of thyroid cancer specimens and that autolo-
gous tumor-reactive TIL can be detected in 43% (n = 7) of thyroid
cancers. Since not every tumor appears to contain TIL capable of rec-
ognizing autologous tumor, strategies to prime tumor-specific T cells
represents an area of interest. DPV-003 is a microvesicle vaccine,
DRibble, that contains more than 80 proteins that are overexpressed
by thyroid cancer (TCGA provisional RNASeq n = 509 pts). The vac-
cine also contains a number of DAMPs and agonist activity for mul-
tiple TLRs packed into stable double membrane microvesicles that
are targeted to CLEC9A+ antigen presenting cells. We are also devel-
oping a second thyroid-specific DRibble vaccine from a cell line de-
rived from an anaplastic thyroid cancer.
Conclusions
Almost half of thyroid cancers evaluated, including one anaplastic
thyroid cancer, contain T cells capable of recognizing autologous
cancer cells and secreting IFN-g. However, the other 50% of thyroid
cancers appear to lack tumor-reactive T cells and may benefit from
combination immunotherapy strategies that include a vaccine.
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Background
Immunotherapies are changing the landscape for cancer treatment; how-
ever, the field is hampered by the lack of biomarkers that can be used
for patient selection and for monitoring treatment responses rapidly and
non-invasively. To address this need, ImaginAb is developing 89Zr-Df-
IAB22M2C, an ~80 kDa minibody (Mb) with high affinity to the CD8
glycoprotein (binding EC50 = 0.4 nM) conjugated with desferrioxamine
(Df) and radiolabeled with the positron emitting radionuclide Zirconium-
89 (89Zr; T1/2 78.4 hours) for imaging CD8+ T cells in humans.
Methods
A comprehensive preclinical program that included evaluation of the
in vitro and in vivo pharmacodynamics of IAB22M2C (unconjugated
Mb), Df-IAB22M2C (conjugated Mb intermediate), Zr-Df-IAB22M2C (Zr
chelated, conjugated non-radiolabeled form of final drug) and 89Zr-
Df-IAB22M2C (radioactive final drug product) was conducted to dem-
onstrate the safety and potential efficacy of the probe.
Results
In vitro studies using human PBMCs from 10 individual human do-
nors showed no measurable or reproducible impact on proliferation,
activation or depletion of CD8+ T cells and no consistent release of
cytokines when donor CD8+ T cells were exposed to soluble or
immobilized Mb protein. Studies that evaluated the effect of saturat-
ing concentrations of 89Zr-Df-IAB22M2C on proliferation and viability
of CD8+ T cells in vitro, also showed no impact on these parameters.
Preclinical imaging and biodistribution studies demonstrated favor-
able pharmacokinetics and the ability of 89Zr-Df-IAB22M2C to detect
infiltrating CD8+ T cells in a mouse hu-PBMC NSG™ GvHD model and
in MatrigelTM plugs implanted with different numbers of human CD8
+ T cells. Radiation dosimetry studies conducted in hu-CD34 NSGTM
mice and the results GLP dosimetry analysis showed that on average,
the organs receiving the largest dose equivalent were the kidneys at
8.0 rem/mCi (2.2 mSv/MBq) followed by the liver at 7.9 rem/mCi(2.1 mSv/MBq) and LLI wall at 6.5 rem/mCi (1.8 mSv/MBq). A GLP
toxicology study was conducted in cynomolgus monkeys that in-
cluded multiple dose cohorts of Zr-Df-IAB22M2C and a vehicle con-
trol. The results showed that doses up to 25 mg/kg of Zr-Df-
IAB22M2C administered weekly to cynomolgus monkeys did not re-
sult in any treatment-related findings in survival, clinical signs, body
weights, food consumption, ophthalmic examinations, electro-
cardiology, blood pressure, heart rate, clinical and anatomic path-
ology, peripheral blood lymphocyte population, and cytokine levels.
Conclusions
89Zr-Df-IAB22M2C has the desired sensitivity and safety profile for im-
aging CD8+ T cells and the first-in-human studies will commence in
the Q4 2016.
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Background
HD IL-2 provides objective responses in 15-20% and durable complete
remission in 5-8% of patients with metastatic melanoma (MM). We pre-
viously identified a gene expression-based tumor subclass character-
ized by immune related genes (Class 2; C2) associated with durable
response to HD IL-2 compared to the remaining tumors that overex-
pressed lineage-associated genes (Class 1; C1). The primary objective of
the HD IL-2 select trial in melanoma was to prospectively validate the
favorable gene expression signature (C2). Secondary objectives were to
seek serum and tissue biomarkers of durable response.
Methods
170 patients with MM were enrolled at 15 Cytokine Working Group
sites from 2010 to 2014. All patients had formalin-fixed paraffin-
embedded (FFPE) tumor tissues identified and blood drawn prior to
HD IL-2. Tumor assessments used WHO criteria and investigator-
assessed outcomes. RNA extracted from FFPE tumor tissues was used
for whole transcriptome profiling by RNA sequencing (114 samples
yielded sufficient RNA, 101 passed default Quality Control (QC)). Pre-
treatment serum from 114 patients served as the test set and was
analyzed using matrix-assisted laser desorption/ionization (MALDI)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 2):91 Page 230 of 242and machine-based learning algorithms to identify a predictive pro-
tein expression signature.
Results
Thirty-one of 170 pts (18.2%) responded, and median overall survival
was 21.3 months, with a 40 month median follow-up. Analysis of
RNAseq from 101 patients whose specimens passed QC showed that
a C2 signature was associated with response to HD IL-2 (normalized
enrichment score 1.70, false discovery rate 0.004). Using MALDI, a
protein expression signature enriched for acute phase proteins (in-
cluding CRP, IL-6, and SAA) was defined in the pre-treatment serum
and used to classify 39 patients into group A (non-acute phase pro-
tein expression) and 75 patients in group B (acute phase protein ex-
pression). Complete response rate in group A was 21% and zero in
group B (p = 0.0001). Two-year PFS rate was 29% in group A com-
pared to 4% in group B (p = 0.0005).
Conclusions
In this prospective biomarker validation study, HD IL-2 produced dur-
able remissions and prolonged survival in patients with MM. A
tumor-derived gene expression signature enriched for immune-
related genes was associated with response. Additionally, preliminary
data with a serum protein signature appears to identify patients
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Background
T-VEC is a herpes simplex virus type-1 based oncolytic immunother-
apy designed to selectively replicate in tumors, produce GM-CSF, and
stimulate antitumor immune responses. Ipilimumab is a checkpoint
inhibitor that promotes T cell activation by blocking negative signal-
ing through CTLA-4. Both agents have demonstrated activity as
monotherapy in advanced melanoma. Based on the potential com-
plementary MOA of the agents, tumor cell lysis and antigen presen-
tation (T-VEC) in combination with T cell checkpoint inhibition, we
hypothesized that improved efficacy was possible when the agents
are used in combination. Because the safety profiles are non-
overlapping, the combination was not anticipated to have significant
increased toxicity. To address these hypotheses, a phase Ib/II study
evaluating the safety and efficacy of T-VEC plus ipilimumab for Stage
III-IV metastatic melanoma was initiated. The phase Ib study was
completed (N = 19) with no DLTs (primary endpoint) or new safety
signals with combination treatment, and an ORR of 50% [1]. Phase Ib
also included biomarker analyses investigating potential pharmaco-
dynamic markers for T-VEC monotherapy and in combination with
ipilimumab.
Methods
Nineteen patients received T-VEC at 106 PFU/mL at week 1, then 108
PFU/mL Q2W from week 4. Ipilimumab was given at 3 mg/kg Q3Wstarting at week 6 for 4 infusions. Peripheral blood was obtained
(Paxgene RNA) at baseline and at weeks 4, 6, 9, and 15. Gene expres-
sion (Agilent Microarray) was analyzed for changes in expression
level with treatment. Pharmacodynamic markers were identified with
a linear mixed effects model. False discovery was controlled with per-
mutation testing.
Results
Gene expression was measured in 16 patients in phase Ib. Most treat-
ment effects on expression were seen after ipilimumab treatment,
but there were a few effects in the initial T-VEC phase that passed
false discovery controls. These T-VEC effects included SELV, SYNPO,
ZBTB32, IQCF2, CDC27, KLK1, PRR20B, CHST6, and IGH. ZBTB32 has
been reported to control the proliferative burst of virus-specific nat-
ural killer cells responding to infection. The combination effects were
enriched for genes involved in lymphoid tissue structure and devel-
opment and immune cell trafficking. 185 of these genes had signs of
a T-VEC effect in the monotherapy phase. These included increases
in GZMM, PDCD1, CD8B, CD8A, and CTLA4 and decreases in IL18,
IRAK3, and TXNRD1.
Conclusions
This hypothesis-generating microarray analysis identified genes up-
regulated in circulating peripheral blood cells after T-VEC monother-
apy and combination treatment. We plan to further evaluate these
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Background
Alpha-tocopheryloxyacetic acid (α-TEA) targets tumor cell mitochon-
dria to release reactive oxygen species (ROS) that induce immuno-
genic cell death (ICD), antigen release, and enhanced antigen cross-
presentation in pre-clinical models. α-TEA is being evaluated for
safety and tolerability in a first-in-human phase I trial in patients with
advanced cancers (NCT02192346). Tumor types in the ongoing trial
include renal cancer, esophageal adenocarcinoma, thyroid cancer,
duodenal cancer, and squamous cell carcinoma of the head and
neck.
Methods
α-TEA lysine salt is administered orally to patients and given daily in
escalating doses for 28 days. Immune monitoring of peripheral whole
blood was conducted for all 12 patients at baseline, and at 1 week
and 4 weeks post-treatment. Plasma levels of α-TEA have been deter-
mined so far in patients receiving 2.4 mg/kg and 4.8 mg/kg α-TEA at
1, 4, 8, and 24 hours after the first dose. Additional samples were
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on those days.
Results
Twelve patients have been treated so far at 2.4 mg/kg and 4.8 mg/
kg dose levels. Eight patients have stable disease, lasting from 1 to
22+ months. One patient showed more than a 2-fold increase in the
number of activated (CD38+ HLA-DR+) effector CD8+ T cells 1 week
post-treatment. A second patient showed more than a 2-fold in-
crease in the number of activated effector memory CD8+ T cells
4 weeks post-treatment. Both patients experienced stable disease
over 5 and 22 months, respectively. Evaluation of α-TEA levels at the
2.4 mg/kg and 4.8 mg/kg doses revealed a proportional increase in
α-TEA plasma levels over a 28-day interval without any indication
that steady state plasma levels were reached. Of the 12 patients, 6
developed atrial fibrillation (AF) after starting α-TEA. The earliest
event occurred 7 days post-treatment, but AF was more common 29-
56 days post-treatment. Four of the 6 patients had a medical history
of AF. These were grade 2 events by CTCAE 4.0 criteria and managed
with appropriate medication without further sequelae.
Conclusions
α-TEA treatment resulted in stable disease in 80% of patients lasting
between 1 and 22+ months. AF was observed commonly in patients
with a medical history of AF, and was managed with appropriate
medication. No clinically meaningful grade 3 or 4 toxicities were ob-
served. Plasma α-TEA levels increased proportionally without any in-
dication that steady state levels were achieved. α-TEA may function
through enhancing pre-existing CD8+ T cell-mediated anti-tumor
activity.
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Background
MGD009 is a B7-H3 x CD3 dual affinity re-targeting (DART) protein.
DART proteins are bispecific, antibody-based molecules that can bind
two distinct antigens simultaneously. MGD009 is designed to redirect
T cells to eliminate B7-H3-expressing target cells through co-engage-
ment of B7-H3 on the target cell and CD3 on the T cell, each in a
monovalent binding manner. MGD009 contains a mutated human
IgG1 Fc domain to reduce/eliminate binding to Fc gamma receptors
(FcγRs) and complement, but retains binding to the neonatal Fc re-
ceptor (FcRn) enabling use of the IgG salvage pathway to prolong its
circulating half-life. B7-H3 protein expression is limited in normal hu-
man tissues, but is overexpressed in a broad range of tumor types,
including melanoma, non-small cell lung cancer (NSCLC), squamous
cell carcinoma of the head and neck (SCCHN), mesothelioma, and
urothelial cancer. By binding to B7-H3 on tumor cells and CD3 on T
lymphocytes, MGD009 can recruit cytotoxic T cells, irrespective of
their ability to recognize cancer cells, and trigger T cell activation, ex-
pansion, and T cell-mediated killing of B7-H3-expressing tumors. The
limited expression of B7-H3 on normal cells should restrict thepotential for cytolytic activity directed at normal tissues, and unin-
tended toxicity in patients treated with MGD009.
Methods
This multi-center, open-label trial is a phase I dose escalation/cohort
expansion study. All patients must have advanced B7-H3-positive tu-
mors. Prior checkpoint inhibitor therapy will be allowed. Dose escal-
ation uses a 3+3+3 design, with patients treated every 2 weeks with
escalating doses of IV MGD009 (starting dose 0.3 ug/kg). The dose
escalation phase enrolls patients with mesothelioma, bladder cancer,
melanoma, SCCHN, NSCLC, clear cell renal cell carcinoma, ovarian
cancer, thyroid cancer, triple-negative breast cancer, pancreatic can-
cer, colon cancer, soft tissue sarcoma, or prostate cancer. Cohort ex-
pansions (n=16/cohort) treated at the maximum tolerated dose will
include patients with melanoma, SCCHN, mesothelioma, urothelial
cancer, and NSCLC. Pre- and on-study biopsies are required for mel-
anoma patients in the cohort expansion phase. Primary and second-
ary study objectives include characterization of the safety,
pharmacokinetics, pharmacodynamics, and preliminary antitumor ac-
tivity of MGD009. All tumor evaluations will be carried out by both
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Background
Lymphomas are the 5th most common cancer in the United States,
and unlike more aggressive lymphomas, indolent non-Hodgkin
lymphoma (iNHL) and is incurable with standard therapy. A previous
trial of in situ vaccination in iNHL combined intratumoral injection of
a TLR9 ligand with radiation to induce a systemic immune response
against tumor. This approach induced tumor-specific CD8+ T cell re-
sponses and durable clinical remissions of patients’ untreated sites of
disease were seen in a minority of patients. One limitation in this
previous trial may have been the scarcity of intratumoral dendritic
cells (DCs); DCs are uniquely able to endocytose dying tumor cells
for cross-presentation to tumor antigen-specific CD8+ T cells. In our
novel iteration of in situ vaccine, intratumoral FMS-like tyrosine kin-
ase 3 ligand (Flt3L) is introduced as a priming step to increase the
presence of intratumoral DCs. Flt3L induced tumor leukocyte infiltra-
tion and regression in lymphoma tumors in pre-clinical trials, and
CDX-301- a formulation of Flt3L - was previously shown to mobilize
BDCA-1 and BDCA-3 myeloid DC subsets in an early phase clinical tri-
als. These DC subsets respond to several TLR agonists and cross-
present antigens more effectively than plasmacytoid DCs (pDCs).
While pDCs are high expressers of TLR9, responsive to CpG, myeloid
dendritic cells express a wider array of TLRs, including high levels of
TLR3.
Methods
This phase I/II trial tests the hypothesis that this novel in situ vaccin-
ation will induce clinical remissions at distant (untreated) tumor sites
in two cohorts of patients with either previously untreated or
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25ug/kg is injected into a palpable lymph node for 9 days, followed
by 2Gy local radiotherapy on day 9 and 10 to the target lymph node.
To activate local DCs, poly-ICLC 2 mg is injected on day 10, 14, 17,
and weekly thereafter for a total of 8 treatments.
Results
Exploratory endpoints include measuring induction of systemic
tumor-specific immune response in pre- and post-vaccine blood and
tissue samples. Using flow cytometry and CyTOF, we have confirmed
that CD1c + (BDCA1+) and CD141+ (BDCA3+) DCs home to treated tu-
mors following treatment with Flt3L and T cells attain a mature ef-
fector phenotype. Tissue from initial bx is being sequenced, and
candidate neoantigens being determined in silico; these neoantigens
are then being synthesized and tested for potential to activate pa-
tient pre- and post-vaccination T cells.
Conclusions
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Background
Inhibition of the PD-1/PD-L1 checkpoint pathway can induce rapid
and durable responses in patients with non-small cell lung cancer
(NSCLC). Unfortunately the majority of patients fail to respond and
there is interest in exploring combinatorial strategies to improve re-
sponse rates. One such strategy is combining checkpoint inhibition
with radiotherapy (RT). We report here our pre-clinical data for com-
bining radiotherapy with PD-L1 checkpoint blockade. These data
demonstrate a clear influence of the sequencing of combinatorial
therapy on its efficacy. Based on these data, we have initiated a clin-
ical trial testing sequencing strategies of radiotherapy with PD-L1 in-
hibition in patients with metastatic NSCLC.
Methods
Using syngeneic mouse tumor models, we tested the synergy of
combining RT with PD-L1 inhibition and the influence of the sequen-
cing of these therapies on efficacy. Based on this preclinical work, we
have initiated a phase II clinical trial testing this combinatorial strat-
egy with three cohorts. The three cohorts are concurrent therapy,
radiotherapy followed by PD-L1 checkpoint blockade, and PD-L1
blockade followed by radiotherapy. We report here the preliminary
safety, efficacy, and correlative science data from interim analysis of
the safety run-in for this trial.
Results
In studies using syngeneic mouse tumor models, we find that PD-L1
inhibition provides no added benefit to radiotherapy alone when ad-
ministered after radiotherapy. Conversely, priming of the immune
system with anti-PD-L1 prior to RT provides significant synergy of the
combinatorial therapy. Our clinical trial has completed enrollment to
the safety-run in of 6 patients. In total, 2 patients experienced grade
3 dose limiting toxicities meeting the criteria for completion of the
safety-run in without the need for dose de-escalation. One patient
experienced asymptomatic grade 3 lymphopenia and one patientexperienced both grade 3 lymphopenia and grade 3 failure to thrive.
At twelve weeks post-treatment initiation, 83% of patients experi-
enced response or disease stability. Three patients (50%) had absco-
pal responses by RECIST criteria, two patients (33%) had stable
disease, and one patient (17%) had progressive disease.
Conclusions
Pre-clinical data suggests that sequencing may be key to the success
of combinatorial strategies of PD-L1 blockade and RT. The safety run-
in for combining PD-L1 checkpoint inhibition with RT suggests that
the combination is safe and tolerable in metastatic NSCLC. The trial
will continue to accrual to evaluate different sequencing strategies
for combining RT and PD-L1 checkpoint blockade. Further study is
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Background
The objective of this study is to identify tissue factor (TF) as a novel
oncotarget for triple negative breast cancer (TNBC) and BRAF mu-
tated melanoma, both of which are very difficult to treat in clinic,
and to develop a novel TF-targeting agent for immunotherapy. To
achieve this goal, Hu developed a second generation TF-targeting
ICON, named L-ICON, which consists of only the light chain (1-152
aa) of FVII fused to an IgG1Fc. The effects of L-ICON were evaluated
as monotherapy or combination therapy with interleukin 15 (IL-15)
for the malignancies.
Methods
TF expression was determined by immunohistochemistry or by flow
cytometry. L-ICON protein (GenBank accession no. KY760097) and
replication-deficient adenoviral vectors have been developed. Bind-
ing activity of L-ICON was determined. Its ADCC effect was evaluated
by an ADCC effector assay and coagulation activity by FVII chromo-
genic activity assay. L-ICON efficacy in monotherapy and combin-
ation therapy with IL-15 was tested in mouse models of murine and
human breast cancer (4 T1 and TNBC MDA-MB-231) and melanoma
(B16F10 and BRAF mutated SK-Mel-28).
Results
TF is over-expressed on TNBC cells and the tumor neovasculature
in over 85% of TNBC patients (n = 14) when using standard
paraffin-embedded tumor tissues or in nearly 60% of TNBC pa-
tients (n = 157) when employing tissue microarray slides. Import-
antly, TF expression is not detected in normal breast tissues.
L-ICON has several important improvements over its first gener-
ation ICON, including (i) more than 50% reduction in molecular
mass, (ii) complete elimination of coagulation activity, (iii) stron-
ger binding activity to TNBC and (iv) more effective as monother-
apy in vivo in orthotopic and subcutaneous mouse models of
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 2):91 Page 233 of 242human TNBC (MDA-MB-231) and murine cancer 4 T1 (an animal
stage IV human breast cancer) and B16F10. L-ICON monotherapy
and combination with IL-15 were effective for the treatment of
SK-Mel-28 in SCID mouse models.
Conclusions
TF is a novel biomarker and oncotarget in TNBC and BRAF- mutated
melanoma. L-ICON, a novel TF-targeting ICON, was effective in mono-
therapy and combination therapy with IL-15 for the treatment of
murine and human TNBC and melanoma in vitro and in vivo in pre-
clinical mouse models.
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Background
Recent developments in immunotherapy have made enormous
strides towards expanding the scope of cancer treatment by target-
ing a patient’s own immune cells. Despite these advances, malignant
melanoma remains a significant clinical issue with a high proportion
of patients remaining unresponsive to therapy and improved, but
still low, complete response rates. The body’s response to stress is
closely integrated with the immune response, yet few cancer treat-
ment strategies account for the relationship between these biological
systems. When the stress response is activated, neurotransmitters,
including norepinephrine, which bind β-adrenergic receptors (βARs)
located on the surface of immune cells, are released, leading to regu-
lation of various immune cell functions. βAR signaling can be pre-
vented pharmaceutically with βAR antagonists (β-blockers) and
considerable literature suggests that these drugs, which are com-
monly prescribed for other indications including hypertension, are
associated with positive outcomes in cancer patients. We examined
the effects of βAR blockade on the efficacy of two immunotherapies
approved to treat metastatic melanoma: IL-2, which promotes T cell
proliferation and αPD-1, which impacts T cell activation.
Methods
C57BL/6 J mice with established B16.F10 melanomas were treated
with β-blockers and immunotherapy (αPD-1, IL-2 or αPD-1/IL-2) and
tumor growth was monitored throughout each treatment regimen.
The accumulation of immune cells within the tumors and lymphoid
tissues were evaluated by flow cytometry at multiple time points fol-
lowing treatment.
Results
Blockade of βAR signaling beginning after tumors were established
had no significant impact on tumor growth. In contrast, attenuation
of tumor growth by each immune-based therapy was improved in
the presence of β-blockers. We observed significantly extended sur-
vival in mice treated with αPD-1 or αPD-1/IL-2 combined with β-
blockers compared to immunotherapy only mice. Most importantly,
the combination of β-blockers, αPD-1 and IL-2 produced a highly sig-
nificant delay in tumor growth and prolonged survival compared to
αPD-1/IL-2 without β-blockers.
Conclusions
Blocking βAR signaling improved the efficacy of at least two types of
immunotherapy, but was most effective when administered with
dual-immunotherapy. We suggest that each therapeutic component
may improve a unique aspect of the immune response to maximallydelay melanoma progression. Due to the availability of all three com-
ponents for use in humans, this therapeutic regimen can potentially
be clinically translated to expand the population of metastatic mel-
anoma patients who experience long term benefits from immune-
based therapies.
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Background
Combination immunotherapy targeting checkpoint molecules has
shown substantial results against solid tumors. However as novel
therapies targeting costimulatory molecules are introduced into the
clinic, successful combination with checkpoint blockade remains un-
certain. Some strongly immunogenic preclinical models have shown
benefit when combining anti-OX40 and anti-PD-1 treatment. In con-
trast, using a PD-1 refractory mammary tumor model we have dem-
onstrated that a significant anti-tumor effect generated with OX40
costimulation is significantly attenuated with the addition of PD-1
blockade. We noted high levels of inflammatory cytokines in the
serum of combination treated mice, and also saw a significant in-
crease in inhibitory receptors TIM-3, LAG-3, and CTLA-4 on CD4+ and
CD8+ T cells in the periphery of treated mice. We hypothesized that
the upregulation of these other inhibitory receptors were limiting the
efficacy of anti-OX40 plus anti-PD-1 combination treatment, and
tested whether sequentially blocking these receptors could augment
therapeutic efficacy.
Methods
Established orthotopically transplanted MMTV-PyMT mammary tu-
mors in FVB/NJ mice were treated with three doses of anti-OX40 and
anti-PD-1 every other day. Serum was taken at time points and
tested for cytokine concentration and spleens were taken two days
after treatment to measure surface expression of inhibitory and costi-
mulatory receptors. Combination treated mice were then followed by
three doses of anti-TIM-3 with or without anti-CTLA-4.
Results
The addition of anti-TIM-3 and CTLA-4 provided no additional impact
to tumor growth compared to that provided by anti-OX40 and anti-
PD-1 (n = 7/group, two independent experiments).
Conclusions
These data demonstrate that TIM-3 and CTLA-4 blockade was not
sufficient to augment the inhibitory effects of the concurrent com-
bination of anti-OX40 and anti-PD-1, and suggest that targeting in-
hibitory receptors upregulated after initial immunotherapy treatment
will require more sophisticated biomarkers and immune monitoring.
Alternatively, we noted significant increases in some costimulatory
receptors (ICOS, 4-1BB) and targeting these receptors may provide
an alternative to blocking inhibitory pathways. Additionally there
may be a tipping point where providing additional antibodies target-
ing costimulatory or checkpoint molecules may be ineffective. T cells
may become so heavily deregulated or over-stimulated that they be-
come permanently exhausted. In support of this we have previously
shown that anti-OX40 combined sequentially with anti-PD-1 provides
superior therapeutic effect compared to concurrent combination,
with complete tumor regression in ~30% of animals treated. Sequen-
tially treated animals generated T cells capable of significantly more
long-term proliferation, suggesting that timing is critical when com-
bining immunotherapies.
Fig. 4 (abstract P14). The addition of anti-TIM + anti-CTLA-4 provides
no benefit to anti-OX40 + anti-PD-1 combination treatment
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Background
Recent success and FDA approval of immune checkpoint inhibitors
(CI) in a growing number of cancers are transforming cancer treat-
ment and revitalizing interest in immunotherapies. However, while
efficacy is observed in patients with advanced metastatic diseases
treated with CI, not all patients respond and most responses are in-
complete. Preclinical studies suggest that combinations of additional
modalities will provide opportunities to improve patient responses.
As both IL-2 and CI therapy can independently augment anti-tumor
immunity in patients, likely in mechanistically distinct ways, we hy-
pothesized we could improve anti-tumor immunity by combining IL-
2 and anti-PD-1 mAb therapy.
Methods
To improve IL-2 efficacy and therapeutic index, we generated novel
anti-IL-2 mAbs which, when complexed with IL-2 (IL-2/mAb) offer ad-
vantages over standard IL-2 therapy [1-3]. First, binding to an anti-IL-
2 mAb increases IL-2 half-life and biological activity. Second, depend-
ing on the epitope at which the mAb binds to IL-2, antibody binding
can modulate which IL-2 receptor subunits (alpha, beta, or gamma)
are engaged. Antibodies that interfere with binding of IL-2Rα can re-
duce activation of high- IL-2Rα-expressing cell types, such as sup-
pressive Tregs, and steer activity toward cell types expressing only IL-
2Rβ and γ. In this way, these complexes may have more effective
anti-tumor activity [1-3]. We screened antibody phage libraries to
identify antibodies that shift IL-2 receptor binding and activity differ-
entially on different cell types in vitro and in vivo. Complexes of these
antibodies were tested in vivo for their effects on T cell frequencyand activation, and in a subcutaneous Lewis lung carcinoma model
for their ability to mediate anti-tumor immunity, both alone and in
combination with anti-PD-1 mAb.
Results
In normal mice, IL-2/mAb complexes potently expanded CD8+ T cells
and NK cells with minimal expansion of Tregs. As single agent ther-
apy, IL-2/mAb complexes or anti-PD-1 mAb reduced tumor growth,
although most mice succumb to tumor growth eventually. Combin-
ation of IL-2/mAb complexes with anti-PD-1 mAb therapy resulted in
durable, complete responses in nearly half of the mice.
Conclusions
While immune based therapies such as anti-PD-1 mAb can be highly
effective in select patients, even in those patients that obtain clinical
benefit, disease may recur. Our results suggest that the addition of
IL-2/mAb complexes to therapy with anti-PD-1 mAb could broadly in-
crease the percentage of patients deriving benefit from immune-
based therapy.
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Background
Administration of antibodies that block the PD-1/PD-L1 pathway
has demonstrated unprecedented success in mediating clinical re-
sponses in patients with advanced cancer. These antibodies are
thought to act by blocking the ability of PD-L1 to mediate an in-
hibitory signal to PD-1 expressing T cells during antigen-
recognition. These antibodies are now FDA-approved for multiple
cancers including non-small cell lung cancer (NSCLC) in patients
with disease that has progressed during or after platinum-based
chemotherapy. In these patients, one in five patients can attain a
clinical response while on checkpoint inhibitor therapy. While
promising, this therapy fails to induce a durable clinical response
in most patients. To overcome this limitation, we hypothesized
that combinatorial therapy with anti-PD-1 mAb and a lymphocyte
growth factor would more effectively augment the expansion of
tumor-reactive lymphocytes. This would also provide a means to
not only remove inhibitory pathways but directly augment the
function of tumor-reactive lymphocytes. We chose to use an IL-
15/IL-15Ra complex (ALT-803) composed of an IL-15 mutant
(N72D) that was pre-associated with the soluble IL-15Ra/Fc fusion
protein. This superagonist complex has been shown to potently
expand and activate CD8+ T cells and NK cells in various animal
models.
Methods
To assess the efficacy of combination therapy, we injected C57BL/6
mice subcutaneously with Lewis lung carcinoma. Mice with estab-
lished tumors were treated with anti-PD-1 mAb and/or IL-15/IL-15Ra
complex, and we monitored tumor progression and changes in im-
mune cell populations in the periphery and tumor.
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The combination of anti-PD-1 mAb and the IL-15/IL-15Ra complex
was substantially more effective at inducing complete responses
compared with administration of either agent alone. Effective ther-
apy was associated with the expansion of CD8+ T cells and NK cells,
and the acquisition of the ability of CD8+ T cells to produce IFNγ
after activation. Interestingly, in vitro, IFNγ led to upregulation of
both MHC and PD-L1 on tumor cells, suggesting a mechanistic basis
for the improved efficacy of the combination therapy.
Conclusions
Our results suggest that the efficacy of anti-PD-1 mAb therapy may
be improved by co-administration of the IL-15/IL-15Ra complex. Our
results also suggest a mechanistic basis for why the combination
may be superior to single agent therapy. To determine if this com-
bination would be of value in human patients, we have initiated a
phase Ib/II clinical trial (NCT02523469) to assess the combination of
anti-PD-1 mAb (nivoluamb) in combination with ALT-803 in patients
with refractory advanced NSCLC.
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Background
The PI3K-Akt signaling pathway modulates diverse biological re-
sponses including signaling, proliferation and survival of T cells. The
identification of a signaling pathway, which differentially regulates
regulatory T cells (Tregs) and conventional T cells (Tconvs), is crucial
for selectively modulating these two subsets. The differential role of
class IA PI3K isoform in regulating the survival and apoptosis of Tregs
and Tconvs has not been elucidated yet.
Methods
For in vitro experiments sorted Tregs and Tconvs were labeled with
CellTrace TM Violet Cell Proliferation stain (VCT) according to the man-
ufacturer’s protocol (Life Technologies, NY). Cells were stimulated
with and without inhibitors. For in vivo experiments C57BL/6 Mice
were injected subcutaneously (s.c.) with TC-1 tumor cells and moni-
tored for development of tumors. Vaccine was given weekly s.c. For
therapeutic experiments vaccine was given weekly throughout the
experiment. CAL-101 treatment was provided on the day when
tumor size reached 3-4 mm 5-6 day before vaccination.
Results
Here, we report that PI3Kd isoform is sufficient for TCR downstream
signaling, proliferation, and survival for either Tconvs or Tregs. In
Tregs, however, PI3Kd is a dominant isoform, where Tregs are fully
dependent on PI3Kd to regulate these properties as PI3Kα and PI3Kb
do not play any role in these biologic processes. On the other hand,
in Tconvs, the two other isoforms, PI3Kα and PI3Kb combined, pro-
vide redundant pathway to PI3Kd in the regulation of TCR signaling,
proliferation and survival. This redundant role provided by PI3Kα and
PI3Kβ isoforms to PI3Kd in Tconvs offers a selective therapeutic ap-
proach to inhibit Tregs, where by inhibiting PI3Kd, signaling, prolifer-
ation, and survival are inhibited in Tregs, while PI3Kα and PI3Kβ, will
provide a path for Tconvs to proliferate and function.
Importantly, we demonstrate that our findings translate to thera-
peutic efficacy in vivo, where the inhibition of PI3Kδ, enhanced anti-
tumor efficacy of antigen-specific vaccine by decreasing the suppres-
sive Tregs and increasing the number of vaccine-induced CD8 T cells,
thus showing synergistic therapeutic effect against tumors. Ourfindings provide a strategy for the selective targeting of Tregs in the
frame of cancer combination immunotherapy.
Conclusions
These findings provide a new insight into CD4 T cell biology and
offer a new strategy for selective targeting of Tregs in the frame of
development of anti-cancer immunotherapies.Combinations: Immunotherapy/
Standard of Care
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Background
Blockade of the programmed death receptor 1 (PD-1) interaction
with its ligands (PD-L1, PD-L2) represents an active therapeutic
approach in recurrent and metastatic SCCHN [1]. This immune
checkpoint may allow immune escape during standard treatment,
including CRT [2]. Standard CRT in SCCHN has substantial toxicity
and the safety of adding PD-1 inhibition is unknown. We report
the first ISA of weekly cisplatin-based CRT in combination with
pembrolizumab, a humanized IgG4 monoclonal antibody inhibitor
of the PD-1:PD-L1/2 interaction.
Methods
This is an open-label phase IB trial of pembrolizumab used in
combination with cisplatin-based, definitive CRT in patents with
stage III-IVB SCCHN. The treatment schema is outlined in Fig. 5.
Key inclusion and exclusion criteria are in Fig. 6. The primary
endpoint of safety is assessed by dose-limiting grade ≥3 adverse
events (AEs) and immune-related AEs (irAEs) per NCI-CTCAE v4.0
criteria. Efficacy is measured by RECIST v1.1 complete response
(CR) rate on 100-day post-CRT imaging and/or pathologic CR for
those who undergo salvage surgery. Planned enrollment is 39 pa-
tients based on a hypothesized CR rate of >60% and a two-stage
Simon minimax design (type I error rate of 0.05 and power of
0.80). Secondary endpoints will include overall response, survival,
and quality-of-life assessments.
Results
At the time of ISA, 27 patients have been enrolled. Patient and
disease characteristics are in Fig. 7. At data cut-off on 9/14/2016,
22 patients have completed CRT. Of those patients, 3 required
cisplatin dose reductions and 6 required a dose discontinuation.
Acute grade (G) ≥ 3 AEs for those completing CRT are in Fig. 8.
Median cumulative cisplatin dose is 225 mg/m2. There were no
radiation dose-limiting toxicities. Two patients (9%) discontinued
pembrolizumab due to irAEs (G2 peripheral motor neuropathy
and G3 transaminase elevation). No deaths have occurred.
Conclusions
This represents one of the first studies to evaluate the safety of con-
current CRT and PD-1 inhibition in SCCHN. Acute CRT-related toxic-
ities are comparable to other SCCHN CRT studies. No new
immunologic safety signals were seen. Further investigation of this
approach is warranted.
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Background
Epidemiological studies show a correlation between physical ac-
tivity and cancer-related mortality [1]. However, the contribution
of immune mediated anti-tumor immunity to the beneficial ef-
fects of exercise has yet to be defined [2]. We sought to investi-
gate if forced running would have a therapeutic benefit in mice
bearing a poorly immunogenic breast cancer and investigate the
immunological changes occurring in response to exercise.
Methods
On day 0 Balb/c mice were inoculated with 4 T1 breast cancer cells
subcutaneously in the right flank (n = 6/group). Starting on day 7,
once tumors were palpable, mice were subjected to 30 minutes of
forced treadmill running (18 cm/sec) five days per week. Control
mice remained sedentary throughout the study. Analysis of immune
cells in spleen and tumor was performed at day 17 and 32 and spon-
taneous lung metastases were evaluated at day 32.
Results
We observed a significantly delayed primary tumor growth
(tumor volume on day 31: 1167 ± 174 mm3 in sedentary versus
847 ± 124 mm3 in exercised mice, p < 0.01) and a tendency for re-
duced metastatic burden in the lungs of exercised compared to
sedentary mice. The progressive marked increase in myeloid-
derived suppressor cells (MDSCs) and splenomegaly seen in sed-
entary 4 T1 tumor-bearing mice was less pronounced in exercised
mice. This difference was significant on day 17; with spleen
weight (520 ± 110 mg in sedentary versus 330 ± 30 mg in exer-
cised mice, p < 0.01) and MDSC frequency in spleen leukocytes
(22.7 ± 2.6% in sedentary versus 14.3 ± 2.7% in exercised mice, p
< 0.001) were significantly lower in exercised mice compared to
sedentary mice. Furthermore, on day 32, the CD8+ T cell/Treg
and CD8+ T cell/MDSC ratio showed a tendency to increase in
tumors from exercised mice.
Conclusions
Our data demonstrate that exercise can slow tumor progression
in a therapeutic setting. While the mechanisms of this effect re-
quire further investigation, the observed decrease in the
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tumor of exercised mice is likely to play a role. Importantly, the
ability of exercise to reduce immunosuppression locally and sys-
temically supports testing exercise in combination with immuno-
therapy as a therapeutic modality that can increase responses
without increasing toxicity.
References
1. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan
A, Alfano CM: Physical activity, biomarkers, and disease outcomes in
cancer survivors: a systematic review. Natl Cancer Inst 2012, 104:815–
840.
2. Koelwyn GJ, Wennerberg E, Demaria S, Jones LW: Exercise in Regulation
of Inflammation-Immune Axis Function in Cancer Initiation and Pro-
gression. Oncology 2015, 29(12).
Not Listed – Other
P20
Systemic immunotherapeutic efficacy of an immunocytokine, NHS-
muIL12, in a superficial murine orthotopic bladder cancer model
Vandeveer Amanda, John W Greiner, Jeffrey Schlom
Laboratory of Tumor Immunology and Biology, Center for Cancer
Research, National Cancer Institute, Bethesda, MD, USA
Correspondence: Vandeveer Amanda (amanda.vandeveer@nih.gov)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 2):P20
Background
Interleukin-12 is one of the most powerful proinflammatory cytokines
capable of supporting T and NK cell function, inducing IFNγ while
driving a TH1 adaptive immune response. Its success as an antitumor
agent in preclinical models has yet to be realized in a clinical setting
due to systemic toxicity. An IL-12 delivery system has been devel-
oped to maximize deposition of the cytokine directly in the tumor
microenvironment (TME), while mitigating the dose-limiting systemic
effects.
Methods
NHS-IL12 is a novel immunocytokine, consisting of two molecules of
human or murine IL-12 fused to a tumor necrosis-targeting human
IgG1 (NHS76). NHS76 recognizes exposed chromatin-DNA found in
necrotic human/murine tumors. Previous studies have shown select-
ive tumor uptake of NHS-IL12 in necrotic subcutaneous murine tu-
mors. Urothelial bladder cancer is known to respond favorably to
immunotherapeutic agents due to many somatic mutations and TILs,
and response to Bacillus Calmette-Guerin (BCG).
Results
We evaluated the use of NHS-muIL12 in a murine orthotopic
bladder cancer model. MB49Luc cells, instilled into the bladder
form superficial, multifocal tumors which can be monitored with
a luciferase-based intravital imaging system. NHS-muIL12 is a very
potent anti-tumor agent in both MB49 tumor models, reducing
tumor volume in a dose-dependent manner. In the intravesical
bladder model, antitumor effects were seen at 2.5 mg/kg admin-
istrated as three separate systemic injections. Mice were cured of
tumor when treated at 20 mg/kgx3 NHS-muIL12 with durable
tumor-free long-term survival. Immune analyses revealed TAA-
specific CTLs and IFN-γ responses, indicating the development of
a specific anti-tumor immune response. An immune memory re-
sponse protected mice following re-challenge with MB49 tumor
cells. Anti-tumor efficacy required CD4+ or CD8+ T cells as deple-
tion of either abrogated the anti-tumor effects. Evaluation of TILs
by FACS, revealed that NHS-muIL12 significantly reduced the
number of immune suppressive cells such as MDSCs, 24 hours
post-treatment, which continued to the end of the study. Im-
munofluorescence showed correlative treatment-related modula-
tion of CD4+ and CD8+ T cells as well as MDSCs and Tregs
within the TME. Gene expression of RNA from bladder tumors,
identified various immune components with immunosuppressive
or immune potentiating roles, modulated by NHS-muIL12
treatment.Conclusions
These data support the possibility that NHS-muIL12 abrogates an
immune-suppressive response within the TME, which might permit T
cells to execute their antitumor effects. NHS-huIL12 (MSB0010360N;
M9241), is currently being evaluated against solid tumors in a phase
I clinical trial (NCT01417546).
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Background
We recently exploited electrostatic interaction to design self-
assembling nanostructures comprised entirely from peptide anti-
gens and toll-like receptor (TLR) agonists as adjuvants. These ma-
terials simplify vaccine composition and exhibit unique properties
such as direct control over the absolute and relative concentra-
tions of each component and co-delivery of the signals to anti-
gen presenting cells. In pre-clinical models of melanoma, this
approach leads to significantly enhanced anti-tumor immunity.
Here, we study how the physicochemical features (e.g., peptide
charge) and relative concentration of each component impact the
internalization, trafficking, and processing of the immune signals
in antigen presenting cells.
Methods
FITC-labeled SIINFEKL peptide was modified with three or nine argi-
nines, for use as a cationic anchor to support self-assembly with a
polyanionic nucleic acid-based TLR3 agonist, polyIC. Hollow capsules
built from these signals were synthesized by coating a sacrificial
CaCO3 core with alternating layers of modified SIINFEKL and PolyIC.
After deposition, the core was removed using EDTA and capsules
were washed with buffer, resulting in stable capsules formed from
immune signals. Capsule size was determined by image analysis and
component loading levels were determined by fluorimetry using
FITC-labeled peptide and Cy5-labeled TLRa. Stability studies were car-
ried out by incubating capsules in media as a function of different
pH and ionic strengths. For uptake and trafficking studies, murine
splenocytes were isolated and treated with different concentrations
of capsules. Cells were analyzed by flow cytometry and imaging in
the presence or absence of inhibitors of endocytic processes and
during staining with markers for surface proteins and intracellular
organelles.
Results
Capsules loaded with FITC-SIINFEKL-R9 and PolyIC were 1-2 μm in
diameter and exhibited similar size and shape for 2 weeks when in
buffer. These materials exhibited tunable loading with a composition
of 15.5% peptide and 84.5% TLRa used for trafficking studies. FITC-
SIINFEKL-R9 and PolyIC capsules were efficiently internalized through
energy dependent processes (i.e., endocytosis) when incubated with
primary dendritic cells within 1 hour of treatment. These effects were
also found to be dose-dependent and did not impact viability of
treated cells.
Conclusions
Initial studies reveal capsules comprised of FITC-SIIN-R9 and
PolyIC are uptaken by primary immune cells quickly and effect-
ively. Ongoing studies will assess the uptake of capsules by
endocytosis in the presence of inhibitors to decipher the endocy-
tic pathway and trafficking of capsules through lysosomes and
endosomes.
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Background
DRibble vaccines are microvesicles derived from proteasome-blocked
autophagosomes. The DPV-001 DRibble vaccine is derived from an
adenocarcinoma and a mixed histology cancer cell line. By mass
spectroscopy they contain more than 130 potential NSCLC antigens,
many as prospective altered-peptide ligands, which could intensify
their immunogenicity. In preclinical models, DRibble immunotherapy
provided significant cross-protection against 8 of 9 tumors tested.
Additionally, Dribble vaccines are effective in treating established tu-
mors in preclinical combination immunotherapy models. We
hypothesize that the efficacy of DRibbles’ vaccination can be attrib-
uted to their capacity to present tumor-derived short-lived proteins
(SLiPs) and defective ribosomal products (DRiPs) that are typically
not processed and presented by professional antigen presenting
cells. These SLiPs and DRiPs embody a prospective pool of tumor an-
tigens against which the host may be less tolerant.
Methods
Thirteen definitively-treated stage III NSCLC patients were vaccinated
at 3-week intervals. Patients were randomized such that some pa-
tients’ intradermal vaccines were combined with administration of
imiquimod or GM-CSF as an adjuvant. PBMCs and serum were col-
lected at baseline and at each vaccination. For one patient, PBMCs
from the baseline visit and week 12 were tested against that patient’s
autologous tumor cell line to measure increased tumor specific T cell
activation. Studies are currently underway to evaluate changes in
TCR repertoires. CD4+ and CD8+ T cells from multiple time points
were sorted and TCR sequencing is being performed to look at alter-
ations in the T cell repertoire. The primary outcome measure of this
clinical trial was to discover if vaccine alone, vaccine plus imiquimod,
or vaccine plus GM-CSF generated the greatest number of strong
antibody response.
Serum from the baseline visit and week 12 was analyzed for in-
creased antibody response to >9000 human proteins using ProtoAr-
rays and Microsphere Affinity Proteomics. Where sufficient tumor
was available, whole exome sequencing was done to evaluatewhether antibody and T cell responses were directed to mutations,
altered peptide ligands or overexpressed normal proteins.
Results
Compared to vaccination alone or vaccination with GM-CSF, vaccin-
ation with DPV-001 plus imiquimod significantly (p < 0.05) increased
the number of antibody responses that were four-fold higher at
week twelve. In the one patient where autologous tumor was avail-
able, vaccination increased the tumor-specific release of TNF-alpha
by peripheral blood CD4 T cells.
Conclusions
Based on these studies, future trials will combine the adjuvant imi-
quimod with DRibble vaccine. Trial Registration
ClinicalTrials.gov identifier: NCT01909752
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Background
Current HPV vaccines are effective at preventing infection. However,
there are no therapeutic vaccines to treat the infection or commonly
associated diseases e.g. CIN, cervical, anal and oral cancers. A therapy
that is simple, effective and safe enough to be administered to CIN
and early-stage cancer patients could be important in achieving the
goal of effective cancer prevention and treatment of pre-metastatic
cancer. We assessed whether PDS0101, a combination of modified
multi-epitope HPV16 peptides (HPVmix) and escalating doses of the
synthetic Versamune® T cell activating platform could facilitate anti-
gen cross-presentation and safe immune activation leading to strong
HPV-specific CD8+ T cell induction in CIN.
Methods
Safety and immunogenicity were assessed in an open label dose es-
calation study. Groups of 3-6 subjects received either low dose
(1 mg), medium dose (3 mg) or high dose (10 mg) of Versamune®
cationic lipid with 2.4 mg of HPVmix. Each subject received one SC
dose every 3 weeks for a total of 3 doses. T cell response was evalu-
ated by IFN-γ and granzyme-b ELISpot using blood drawn from the
subjects pre-vaccination, 2 weeks after each vaccination and 90 days
after vaccination 3. The trial is registered at ClinicalTrials.gov (number
NCT02065973).
Results
No serious adverse events were reported. No IND safety reports were
submitted. No subjects withdrew. Strong HPV-specific T cell re-
sponses occurred at all 3 doses, even in those subjects with low pre-
vaccination T cell responses. PDS0101 vaccination led to strong T cell
responses evaluated by both IFN-γ and granzyme-b ELISpot. Conclu-
sions: PDS0101 is safe and effectively performs antigen cross-
presentation as demonstrated by HPV-specific T cell responses, in-
cluding inducing active cytolytic T cells. Clinical benefit in CIN2/3 and
cancer will be evaluated in larger phase II trials.
Conclusions
PDS0101 is safe and effectively performs antigen cross-presentation
as demonstrated by HPV-specific T cell responses, including inducing
active cytolytic T cells. Clinical benefit in CIN2/3 and cancer will be
evaluated in larger phase II trials.
Trial Registration
ClinicalTrials.gov identifier: NCT02065973
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Background
Application of TLR7 activator imiquimod (IMQ) onto BCC of the skin
leads to an early tumoral transcriptional profile of immunological re-
jection (ICR) preceding complete remission as shown in a random-
ized trial [1]. Here we employed the same methodology evaluating
serial FNA tumor biopsies from breast cancer patients treated on a
clinical trial of the combination of IMQ and radiotherapy (RT), to de-
lineate dynamic changes associated with ICR in breast cancer and to
understand the contribution of each treatment modality to antitumor
immunity in vivo. We previously demonstrated synergy of IMQ/RT in
the poorly immunogenic TSA model with enhanced T cell-mediated
inhibition of treated and untreated tumors [2].
Methods
Clinical trial (NCT01421017): for patients with metastatic breast can-
cer to the skin. Treatment: topical IMQ to one metastasis, IMQ and
RT to another metastasis. IMQ self-applied 5xX/per week x 8 weeks,
RT started with first IMQ (6Gyx5 over 10 days). Cyclophosphamide
(200 mg/m2 IV) was administered a week before in a subset of pa-
tients. An untreated, measurable lesion (skin or distant metastases)
outside the IMQ and radiation fields was observed as systemic re-
sponse read-out per RECIST1.1. Local response defined as PR or CR in
treated lesions. FNA of IMQ and IMQ/RT treated metastases: at base-
line, 2 and 3 weeks, RNA isolation/amplification performed per SOPs.
Gene expression: Affymetrix Human GeneArray 1.0 ST/Partek Genom-
ics suite software with special emphasis on expected immune
signature.
Results
Serial FNA samples are available from 18 patients. Gene expression
profiles of baseline biopsy treated with IMQ/RT identified 2309 differ-
entially expressed genes (p < 0.005) between CR and PR. Among
them, ICR genes such as GZMB, GZMH, PRF1, GNLY, CD8A and TBX21
are over expressed in CR. Significant altered gene expression was ob-
served in progressing lesions (week 3 vs baseline, 1854 genes) in
contrast to responding metastases (PR: 53 genes, CR: 23 genes) post
IMQ/RT suggesting active wound healing and tumor progression sig-
nature. For the IMQ alone treated metastases, differential gene ex-
pression was observed at baseline distinguishing subsequent PR and
PD (n = 189, p < 0.005). Systemic response was observed as a marked
baseline gene expression difference (n = 1177, p < 0.005) predicting
abscopal phenomena (CR, PR, SD and PD).
Conclusions
The ICR signature in tumors before IMQ-RT treatment is positively
correlated with complete local response, which validates the ICR hy-
pothesis in metastatic breast cancer. Systemic response consistent
with induction and/or boosting of adaptive immunity is predicted by
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Background
Increasing evidence has illustrated that enhanced lymphocytic infil-
tration is a powerful prognostic marker in colon cancer (CC). The
Immunoscore (IM) methodology was developed as a standardized
assay to quantify the in situ immune cell infiltrate.
Methods
The Society for Immunotherapy of Cancer (SITC) led an international
consortium, initiated with 23 expert centers from 17 countries, to evalu-
ate the Immunoscore in routine clinical settings. CC patients (pts)
stages I/II/III with no prior neo-adjuvant treatment were included in this
study. Overall, 3855 pts split into a training set (TS), internal validation
set (IVS), and external validation set (EVS) were quantified for IM using
Fig. 9 (abstract P26). Demographic Characteristics of Melanoma
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 2):91 Page 240 of 242immunohistochemistry with CD3/CD8 antibodies and digital pathology
quantification of whole slide sections. All statistical analyses were pre-
defined and performed by external statisticians. The primary endpoint
was time-to-recurrence (TTR); multivariate analyses were performed
using Cox models adjusted for IM, age, gender, T-stage, N-stage, and
stratified by participating center.
Results
Across centers, the median recurrent follow-up was 126.6 months. Pt
characteristics: 51.5% male, median age 69 years, and 17%/54%/29%
stage I/II/III, respectively. Among pts with stages I-III CC in the TS, TTR
was shorter among 152 pts (22%) with Low-IM CC vs. 548 pts with
High-IM CC (HR [95% CI], 0.41 [0.28-0.61]; P < 0.0001). In the IVS, TTR
was also shorter among 155 pts with Low-IM CC vs. 481 pts with
High-IM CC (0.41 [0.27-0.65]; P < 0.0001). In the EVS, TTR was also
shorter among 225 pts with Low-IM CC vs. 744 pts with High-IM CC
(0.51 [0.38-0.68]; P < 0.0001). These results were independent of age,
sex, tumor stage, and sidedness. Among secondary objectives, Immu-
noscore groups (High, Int, Low) predicted time to recurrence in the
TS (0.19 [0.10-0.37]; P < 0.0001), IVS (0.27 [0.14-0.53]; P < 0.0001), and
EVS (0.33 [0.22-0.49]; P < 0.0001). In stage II CC pts (1433), the differ-
ence in TTR was significant between the Low and High-Immunoscore
groups (0.36 [0.23-0.56]; P < 0.0001). In multivariate models, Immuno-
score grouping (2, 3, or 5) was significant (C-index : 0.73 [0.66-0.80],
all P < 0.0001). Multivariate models including MSI and sidedness were
performed and will also be presented. Reproducibility of the IM assay
was validated across centers.
Conclusions
The primary and secondary endpoints of the global Immunoscore
study were reached. Overall, TTR was significantly longer in pts with
stages I-III CC defined as High-IM. Moreover, a subgroup of patients
with high-risk stage II CC was also identified by Low-IM.
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Background
Precise biomarkers are urgently needed to characterize the tumor
immune micro-environment, both for prognostication and to predict
the benefit of immuno-therapeutic intervention. HLA-DR on tumor
cells and Ki67 on cytotoxic (CD8+) T cells have been proposed as
biomarkers of anti-PD1 activity. Multiplex immunohistochemistry
(mIHC) allows for automated quantitation of phenotypes and spatial
distributions of immune cell populations within formalin fixed paraf-
fin embedded (FFPE) tissues.
Methods
In order to test whether mIHC can better characterize the tumor im-
mune microenvironment, we screened databases at the Herbert Irving
Cancer Center (HICC) at Columbia University for early stage melanoma
patients with available FFPE primary melanoma tissue anddocumented clinical follow up. We identified a preliminary population
of 31 stage II-III melanoma patients diagnosed between 2000 and
2012, with characteristics shown in Fig. 9 for whom pathology from
the primary biopsy was shown. Clinical follow up was available on 18
patients of whom 9 patients were alive with no evidence of recur-
rence, 1 had died of another malignancy, and 7 had died of melan-
oma. 15 patients had more than 24 months of survival information
available but no detailed clinical information. 5 μm slides from either
the primary biopsy or subsequent wide local excision procedure were
stained using Opal multiplex IHC for DAPI, CD3 (LN10, Leica), CD8
(4B11, Leica), CD68 (KP1, Biogenex), SOX10 (BC34, Biocare), HLA-DR
(LN-3, Abcam) and Ki67 (MIB1, Abcam). Cell phenotypes within repre-
sentative fields pre-selected by a trained dermato-pathologist and
were visualized using the Mantra quantitative pathology workstation
(Perkin Elmer), and analysis of spatial distribution of CD3 + CD8+ cells
analyzed as shown in Figs. 10 and 11 using inForm® image analysis
software (Perkin Elmer), and Spotfire software (TIBCO).
Results
CD3 + CD8+ cells are closer to both tumor (SOX10+) and CD68+ cells
when they express HLA-DR (p < 0.001). Conversely, CD3 + CD8+ cells
are significantly farther from Sox10+ cells when they express Ki-67.
Among patients with clinical follow up, CD3 + CD8+ cells in non-
recurrent patients were closer to SOX10+HLA-DR+ cells than they
were in recurrent patients(p < 0.001).
Conclusions
If proximity is a surrogate for interaction, these data may indicate
that HLA-DR expression enhances interaction with T cells for both
CD68+ infiltrating cells and Sox10+ tumor cells. In addition,
CD3+CD8+ cells were closer to SOX10+HLA-DR+ cells in patients who
did not recur, which is interesting in light of recent data showing that
expression of HLA-DR by tumor cells increases likelihood of response to
anti-PD1. Further staining and analysis of annotated tumor samples
from the complete HICCC cohort 2000-2012 is ongoing and results will
be updated at time of presentation.
Fig. 11 (abstract P26). Distance between CD3 + CD8+ T cells and
nearest neighbor be recurrence status, Top Left: Mean distance from
CD3 + CD8+ to CD68 + HLA-DR- by recurrence status, Lower Left:
Mean distance from CD3 + CD8+ to CD68 + HLA-DR+ by recurrence
status. Top Right: Mean distance from CD3 + CD8+ to SOX10 + HLA-
DR- by recurrence status, Bottom Right: Mean distance from CD3 +
CD8+ to SOX10 + HLA-DR+ by recurrence status
Fig. 10 (abstract P26). Distance between CD3 + CD8+ T cells and
nearest neighbor, Left: Mean distance from CD3 + CD8+ to CD68 +
HLA-DR- (light blue) or CD68 + HLA-DR+ (dark blue), Center: Mean
distance from CD3 + CD8+ to SOX10 + HLA-DR- (pink) or SOX10 +
HLA-DR+ red), Right: Mean distance from CD3 + CD8+ to SOX10 +
Ki67- (pink) or SOX10 + Ki67+ red)
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Background
Imprime PGG (Imprime) is a soluble, intravenously (iv) administered
yeast 1,3/1,6 β-glucan PAMP (pathogen-associated molecular pattern).
As a PAMP, Imprime triggers innate immune function, including direct
tumor killing, repolarization of the immunosuppressive tumormicroenvironment (flipping immunosuppressive M2 macrophages to
an anti-tumor M1 state), and T cell expansion and activation via den-
dritic cell maturation and antigen presentation. Clinically, Imprime has
demonstrated promising efficacy in clinical trials when combined with
tumor-targeting or anti-angiogenic antibodies. Phase II studies with
pembrolizumab are starting in both metastatic triple negative breast
cancer and metastatic melanoma. Herein, we have employed multi-
plexed immunofluorescence to profile the immune microenvironment
in preclinical tumor tissues.
Methods
The B16F10 experimental metastasis model was used to interro-
gate Imprime’s anti-tumor activity in vivo. B16F10 melanoma cells
were injected into the tail vein of syngeneic C57BL/6 mice, seed-
ing the lungs with B16 foci. Outgrowth of these metastatic foci
was assessed after treatment with the tumor-targeting anti-tryp1
antibody TA99, Imprime, or the combination. At various times
post tumor injection, lungs were examined via multiplexed im-
munofluorescence (IFC) for markers of immune infiltration and
activation. IFC was performed using 7-color staining (Opal tech-
nology, PerkinElmer) combined with in situ hybridization (RNA-
Scope, ACD). Images were acquired with the Vectra3 multispectral
imaging system and cells segmented using Inform (PerkinElmer).
Imaging data were transformed into “.fcs” files and analyzed
using Flowjo flow cytometry software (Treestar)). Relational pa-
rameters such as immune cell clustering and tumor infiltration
were performed via custom algorithms in R.
Results
TA99 alone suppressed the outgrowth of B16 lung metastases by
54% when compared to vehicle treatment. The combination of
Imprime with TA99 reduced the number of metastases even more
profoundly (96% vs vehicle). IFC analyses showed that Imprime
specifically accumulates in the tumor stroma, binds to macro-
phages and elicits increased iNOS production, indicating the re-
polarization of these macrophages to a more M1-like, inflamma-
tory state. Imprime-treatment also triggered the formation of large
immune cell clusters, possibly representing resolved tumor nests
or the establishment of tertiary lymphoid tissues, both of which
have been identified as predictors of successful anti-tumor im-
mune responses. Finally, Imprime treatment and localization at the
tumor site corresponds with substantial upregulation of the gene
Mx1- a type 1 interferon-responsive gene.
Conclusions
Imprime is a potent immunomodulator that induces a coordi-
nated immune attack in vivo demonstrated by immune cell
binding, M1 re-polarization and a type-1 interferon signature
that coincides with reduced outgrowth of established ling
metastases.
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Background
Systemic delivery of anti-PD1 antibody therapy has proven rela-
tively safe in glioma patients, but therapeutic response remains
unpredictable and persistently low. Checkpoint blockade anti-
bodies face numerous potential confounders in these tumors,
such as the blood-brain barrier, poor local or lymph node presen-
tation of tumor antigens, and unknown dependency on PD-1/PD-
L1 activity during tumor progression. Here, we conducted a pilot
study using intracranial convection-enhanced delivery (CED) of
anti-PD1 (mDX400) into a de novo murine glioma model to the
dissect tumor and immune perturbations following local treat-
ment, and to compare the efficacy of treating during early or late
tumor progression.
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Transgenic C57BL/6-PTEN(fl/fl) mice were injected with a retro-
virus expressing PDGFb and cre recombinase, inducing tumori-
genesis as previously described. In this model, with a median
survival of 80 days post-tumor induction (D80), convergence to a
stereotyped subset of genomic rearrangements occurs by ap-
proximately D35. Intracranial osmotic pumps filled with mDX400
or isotype control antibody solution were implanted at the tumor
site for 14-day windows spanning (D28-D42) or following (D42-
D56) this developmental transition, then removed. Tumor burden
was monitored by bioluminescence (luciferase reporter), and mice
were sacrificed upon presentation of tumor-related morbidity. Tis-
sue was formalin-fixed for histopathology and cryopreserved for
gene expression analysis.
Results
During both treatment windows, tumor burden decreased differen-
tially in mDX400-treated mice. While survival time between mDX400-
and isotype-treated mice was nearly identical for D28-D42 (both
median D70), for mice treated between D42-D56, median survival
differed (D88 vs. D68), but without statistical significance between
the groups (p = 0.25). Interestingly, the D42-D56 mDX400 groupproduced several “long-term survivors”, who lived up to 158 days
with stable tumor burden. While substantial T cell infiltration was
detected in the end-stage tumors of both mDX400- and isotype-
treated mice by immunohistochemistry (CD3e), expression of im-
mune signaling pathways (e.g., Fc receptor and Toll-like receptor
families, phagosome/lysosome components), was significantly higher
among three long-surviving mDX400-treated mice than in three
isotype-treated mice.
Conclusions
Our pilot study of mDX400 administration by CED identified an impact
on tumor burden during and following therapy, but a lack of survival
benefit for D28-D42 treatment. While additional experiments are needed
to statistically evaluate survival benefit for the later treatment window,
differentially high intratumoral expression of genes reflecting immune ac-
tivation among mDX400-treated, long-surviving mice demonstrates that
molecular study in this model may elucidate intratumoral conditions as-
sociated with response to anti-PD1 blockade in glioma.
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